Homologous Recombination Deficiency (HRD) is associated with sensitivity towards PARP inhibitors (PARPi) and its determination is used as a biomarker for therapy decision making. Here, PARP1 is linked to hypoparathyroidism-retardation-dysmorphism syndrome.